1. HBW Insight
  2. >>Archive

In Brief

FDA pushes back deadlines for compliance with its final rule for sunscreen labeling and effectiveness testing, giving manufacturers an additional six months for products with annual sales of at least $25,000. More news in brief.

FDA gives sunscreen manufacturers an eleventh-hour extension to comply with new labeling and effectiveness testing requirements. The agency has pushed the deadline back six months for sunscreen products to undergo broad-spectrum testing and amend label claims to reflect test results. Firms now must comply with the rule by Dec. 17, 2012 for all products with annual sales of $25,000 and up, and by Dec. 17, 2013 for other products, according to a notice in the May 11 Federal Register. FDA’s decision to extend the deadline is based on information submitted in joint comments from the Personal Care Products Council and the Consumer Healthcare Products Association, which warned the agency that a “shortage” of sunscreen products could occur in summer 2012 if manufacturers were not given an additional six months to bring their products into compliance with the new requirements. The groups cited the limited capacity of testing facilities and argued that complex label redesigns, such as on glass or plastic containers, would take longer than the one year the agency originally granted Also see "Industry Needs More Time To Comply With Sunscreen Testing, Labeling Rule" - HBW Insight, 29 August, 2011..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

FTC Consumer Privacy Policy Driven By ‘Straw Man’ Arguments – Commissioner Holyoak

 
• By Eileen Francis

The US FTC’s contention that ‘notice and choice’ has failed as the cornerstone of consumer privacy regulation and must be abandoned in favor of data minimization and other more stringent measures does not adequately account for the complexity of business practices and consumer behavior, FTC commissioner Melissa Holyoak asserted at the NAD’s 2024 Annual Conference.

FTC’s New Commissioner ‘Dismayed’ By Agency Overreach

 
• By Eileen Francis

FTC Commissioner Melissa Holyoak says the agency has acted outside the bounds afforded by Congress, citing several areas within consumer protection, including a recent update to the final rule for the Health Breach Notification Rule and the commission’s use of notices of penalty offense to serve as the basis for Section 5 settlements. 

Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

 
• By Eileen Francis

At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

More from HBW Insight

People On The Move: Appointments At Maxwellia, Nestlé, Alland & Robert

 
• By Tom Gallen

A round-up of the latest European health & wellness market moves: Maxwellia names chief operating officer; Nestle appoints marketing & sales head; Alland & Robert gets deputy general manager.

Good News? 90-Day Pause On Most Tariff Changes – Bad News? 125% Rate Imposed Against China

 
• By Malcolm Spicer

US businesses across industry sectors remain apprehensive about higher tariffs going into effect on imports from China after three-month pause allowed on other changes.

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 
• By Jessica Merrill

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.